Arctic Bioscience – HeROPA 1-year read-out: Top-line results expected within 2-3 weeks

All patients have completed 1 year of treatment and the HeROPA phase 2b clinical trial on HRO350 in mild-to-moderate psoriasis is completed. Top-line results were planned to be announced by end of Q1 2025, however cleaning of the comprehensive dataset from more than 500 patients for 1 year of treatment is taking more time than anticipated. The top-line data are currently being cleaned and quality controlled. Top-line results are expected to be published within 2-3 weeks.

Analyses on all endpoints will then be presented in the full clinical study report in May this year.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.